# Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma

> **NCT04802031** · PHASE2 · WITHDRAWN · sponsor: **Thomas Martin, MD**

## Conditions studied

- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Rapid Infusion Isatuximab

## Key facts

- **NCT ID:** NCT04802031
- **Lead sponsor:** Thomas Martin, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-05-28
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2022-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04802031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04802031, "Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04802031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*